From the perspective of patients with other diseases, CDF basically does not pay any other expenses. Increasing spending on low-value, low-cost cancer treatment essentially means that funds will be diverted from more beneficial medical services. For example, high spending on borderline cancer drugs basically means less investment in surgery, early treatment, social services, and nursing support. This is unfair to many other patients. At the same time, many cancer treatments prescribed at the end of life have nothing to do with improving the quality of life (Prigerson et al., 2015). With a fixed budget, there is no doubt that there are better ways to spend healthcare than expensive marginal or remote cancer drugs.
正在翻译中..